Early phase I data on lutetium (177Lu) rhPSMA-10.1 for the treatment of metastatic castration-resistant prostate cancer (mCRPC) has demonstrated an encouraging safety profile for the novel radioligand therapy. Developed by Blue Earth Therapeutics Ltd, 177Lu rhPSMA-10.1 was administered to patients in the phase I trial in July. Radiation dosimetry that was conducted for up to 3 cycles revealed high radiation doses absorbed by the tumor relative to the dose received by key normal organs, including the kidneys and salivary glands. ...